Aslan Pharmaceuticals

NCT01721148

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

NCT01992367

Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003

NCT02648425

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

NCT02435927

ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

NCT02342652

A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects

NCT03082053

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

NCT03368846

Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

NCT03721263

Study of ASLAN004 in Healthy Subjects

NCT04090229

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis